Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Authors :: Yost, Kathleen J
Rothe, Michael
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Duvivier, Herbert Leon
Ahn, Eugene R.
Cannon, Timothy Lewis
Chiu, Vi Kien
Khalil, Maged F.
Kim, Brian
Prinz, Allison Marie
Grantham, Gina N.
Gregory, Abby
Hinshaw, Dominique C.
Halabi, Susan
Schilsky, Richard L.
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p106-106, 235p
Publication Year :: 2024

Full Text Access

Tools